Watchlist Price Alert

Phathom Pharmaceuticals I... (PHAT)

NASDAQ: PHAT · Real-Time Price · USD

2.40

0.00 (0.00%)

At close: May 07, 2025, 3:59 PM

2.45

2.30%

After-hours: May 07, 2025, 06:44 PM EDT

0.00% (1D)

Bid	2.36
Market Cap	166.81M
Revenue (ttm)	81.86M
Net Income (ttm)	-251.47M
EPS (ttm)	-5.18
PE Ratio (ttm)	-0.46
Forward PE	-1.31
Analyst	Buy

Ask	2.47
Volume	1,888,468
Avg. Volume (20D)	1,374,203
Open	2.41
Previous Close	2.40
Day's Range	2.38 - 2.54
52-Week Range	2.38 - 19.71
Beta	0.15

About PHAT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PHAT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PHAT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Phathom Pharmaceuticals has released their quartely earnings on May 1, 2025:

Revenue of $28.52M misses estimates by $501K, with 1391.58% YoY growth.

EPS of -1.07 misses estimates by 0.00, with 3.60% YoY growth.

Why Price Moved

5 days ago

-17.86%

Phathom Pharmaceuticals shares are trading lower a... Unlock content with Pro Subscription

6 days ago

-21.68%

Phathom Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 EPS and Sales results.

News

6 days ago · seekingalpha.com

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript

6 days ago · zacks.com

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.42 per share a year ago.

2 weeks ago · businesswire.com

Frazier Life Sciences Appoints Aditya Kohli to Partner

PALO ALTO, Calif.--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. ...

2 months ago · seekingalpha.com

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Eric Sciorilli - Head, Investor Relations Terrie Curran - President & Chief ...

2 months ago · zacks.com

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $0.80 per share a year ago.